1 Is there a causal relationship between executive function and liability to mental health

2 and substance use? A Mendelian randomisation approach

3 Sabrina M. I. Burton¹, Hannah M. Sallis^{1,2,3}, Alexander S. Hatoum⁴, Marcus R. Munafò^{1,2,5},

4 Zoe E. Reed^{1,2*}

- 5 1 School of Psychological Science, University of Bristol, Bristol, UK
- 6 2 MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK
- 7 3 Centre for Academic Mental Health, Population Health Sciences, University of Bristol,
- 8 Bristol, UK
- 9 4 Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA
- 10 5 National Institute for Health Research Bristol Biomedical Research Centre, University
- 11 Hospitals Bristol NHS Foundation Trust and University of Bristol, Bristol, UK
- 12 *Corresponding author

13 Abstract

14 **Background:** Executive function consists of several cognitive control processes that are able to regulate lower level processes. Poorer performance in tasks designed to test executive 15 16 function is associated with a range of psychopathologies such as schizophrenia, major 17 depressive disorder (MDD) and anxiety, as well as with smoking and alcohol consumption. Despite these well-documented associations, whether they reflect causal relationships, and 18 if so in what direction, remains unclear. We aimed to establish whether there is a causal 19 20 relationship between a latent factor for performance on multiple executive function tasks -21 which we refer to as common executive function (cEF) – and liability to schizophrenia, MDD, 22 anxiety, smoking initiation, alcohol consumption, alcohol dependence and cannabis use 23 disorder (CUD), and the directionality of any relationship observed.

Methods: We used a two-sample bidirectional Mendelian randomisation (MR) approach using genome-wide association study (GWAS) summary data from large cohorts (N=17,310 to 848,460) to examine whether causal relationships exist, and if so in which direction.

27 Results: We found evidence of a causal effect of increased cEF on reduced schizophrenia liability (IVW: OR=0.10; 95% CI 0.05 to 0.19; p-value=3.43x10⁻¹²), reduced MDD liability (IVW: 28 OR=0.52; 95% CI 0.38 to 0.72; p-value= 5.23×10^{-05}), decreased drinks per week (IVW: β =-0.06; 29 95% CI -0.10 to -0.02; p-value=0.003), and reduced CUD liability (IVW: OR=0.27; 95% CI 0.12 30 to 0.61; p-value=1.58x10⁻⁰³). We also found evidence of a causal effect of increased 31 32 schizophrenia liability on decreased cEF (IVW: β =-0.04; 95% CI -0.04 to -0.03; p-value=3.25x10⁻ ²⁷), as well as smoking initiation on decreased cEF (IVW: β =-0.06; 95%CI -0.09 to -0.03; p-33 value=6.11x10⁻⁰⁵). 34

35 **Conclusion:** Our results indicate a potential bidirectional causal relationship between a latent 36 factor measure of executive function (cEF) and schizophrenia liability, a possible causal effect 37 of increased cEF on reduced MDD liability, CUD liability, and alcohol consumption, and a 38 possible causal effect of smoking initiation on decreased cEF. These results suggest that 39 executive function should be considered as a potential risk factor for some mental health and 40 substance use outcomes, and may also be impacted by mental health (particularly schizophrenia). Further studies are required to improve our understanding of the underlying 41 42 mechanisms of these effects, but our results suggest that executive function may be a 43 promising intervention target. These results may therefore inform the prioritisation of experimental medicine studies (e.g., of executive function interventions), for both mental 44 health and substance use outcomes, to improve the likelihood of successful translation. 45

46 Introduction

The ability to perform nearly all of the activities required for daily living is mediated by
executive function (EF)¹ – the ability to perform self-directed behaviour toward a goal and
to enable self-regulation. The prefrontal cortex is the neural substrate of EF, including
cognitive control functions that regulate lower-level processes such as decision making¹.
There are different aspects of EF, including inhibitory control, working memory and task
switching.

EF is thought to be impaired in individuals with a range of mental health problems¹, and 53 54 there is evidence that it is also associated with substance use². For example, poorer EF has been observed among individuals with schizophrenia^{1,3–5}, major depressive disorder 55 (MDD)^{6,7}, and anxiety^{8,9}, as well as in people who smoke both cigarettes^{10,11} and 56 cannabis^{12,13} and consume alcohol^{10,14}. The direction of association between EF and these 57 phenotypes is unclear¹, with some studies suggesting EF deficits prior to these² and others 58 59 suggesting they occur after³. It is unclear whether these associations represent causal 60 pathways, and if so what the direction of any causal effect might be. EF is potentially modifiable¹⁵, and drug repurposing analyses for a common EF factor (cEF) score¹⁶ have 61 suggested that this cEF may also be modifiable. Therefore, if we can better understand the 62 63 relationship between EF and mental health and substance use outcomes, this will help to 64 inform intervention development.

65 Mendelian randomisation (MR) is a well-established method for causal inference, which relies 66 on approximations of Mendel's laws of segregation and random assortment¹⁷. MR is based 67 on instrumental variable (IV) analysis, with single nucleotide polymorphisms (SNPs) that are 68 robustly associated with the exposure used as IVs. MR is subject to three core assumptions:

69 i) the genetic instrument is robustly associated with the exposure of interest (relevance), ii) 70 there is no confounding of the genetic instrument and the outcome (independence), and iii) 71 the genetic instrument only influences the outcome via the exposure (exclusion restriction). 72 There are different MR methods that test potential violations of these assumptions and 73 therefore a consistent effect estimate across different approaches would provide greater 74 evidence of a truly causal effect, robust to the assumptions of MR. MR minimises the effect of confounding variables as the genetic variants are randomly assigned at conception¹⁸. It also 75 76 overcomes issues around reverse causation as these genetic variants precede any outcomes¹⁹. 77

78 Summary data from genome-wide association studies (GWAS) can be used as the genetic instruments in MR. A recent GWAS of cEF score, conducted in the UK Biobank (European 79 ancestry), identified 90 genome-wide significant hits¹⁶. The factor score was created from 80 81 five different EF tasks – trail making, symbol-digit substitution, digit span, prospective 82 memory, and pairs memory – using confirmatory factor analysis. Unlike, previous studies 83 focusing on specific EF tasks, the cEF incorporates multiple facets which may better capture 84 the cognitive component of psychopathology. In particular, single executive function tasks are noisy measures of executive functioning, with large method variance components 85 reflecting lower level cognitive processes (the "task impurity problem"²⁰). By combining 86 87 multiple tasks, we can create a more "pure" measure of executive functioning. Further, past 88 work has shown that this common component is correlated with – but separable from – IQ, 89 and is genetically associated with psychopathology over and above the genetic influence of 90 other cognitive factors¹⁶.

91

92 We examined whether there were causal relationships between EF and a range of mental 93 health and substance use phenotypes, and the direction of any effect – for example, does 94 poor mental health lead to poorer EF, or vice versa? We did this by applying a two-sample MR 95 approach, where the SNP-exposure and SNP-outcome estimates are obtained from genome-96 wide association studies (GWAS) in independent samples and used to estimate causal effects. 97 We focused on schizophrenia, MDD, anxiety, smoking initiation, alcohol consumption (drinks 98 per week), alcohol dependence, and cannabis use disorder (CUD), using a bidirectional approach to determine the causal direction of these relationships. 99

- 100 Methods
- 101 Data Sources
- 102 We used GWAS data from several studies, shown in Table 1. To minimise sample overlap,
- 103 we excluded some samples that contributed to the original GWAS in our analyses, as
- indicated in Table 1.
- **Table 1**. GWAS for executive function, mental health and substance use outcomes.

Phenotype	Author	Sample	Final N
Executive function	Hatoum et al, 2020 ¹⁶	ИКВВ	427,037
Schizophrenia	Schizophrenia Working Group of the PGC, 2020 ²¹	PGC	Cases = 69,369 Controls = 236,642
Major depressive disorder	Wray et al, 2018 ²²	PGC, excluding UKBB and 23andMe	Cases = 45,396 Controls = 97,250
Anxiety	Otowa et al, 2016 ²³	ANGST	Cases = 5,712 Controls = 11,598
Smoking initiation	Liu et al, 2019 ²⁴	GSCAN, excluding UKBB	848,460
Drinks per week	Liu et al, 2019 ²⁴	GSCAN, excluding UKBB	630,154
Alcohol dependence	Walters et al 2018 ²⁵	PGC Substance Use Disorders working group	Cases = 8,485 Controls = 20,272
Cannabis use disorder	Johnson et al, 2020 ²⁶	PGC Substance Use Disorders working group, iPSYCH and deCODE	Cases = 14,080 Controls = 343,736

- 106 UKBB= UK Biobank, PGC= Psychiatric Genomics Consortium, ANGST= Anxiety NeuroGenetics Study,
- 107 GSCAN= GWAS and Sequencing Consortium of Alcohol and Nicotine use

Executive function. We used summary data from the most recent GWAS of cEF¹⁶, which
 identified 90 independent genome-wide significant (p<5x10⁻⁰⁸) SNPs associated with a cEF
 score, where a higher score reflects increased EF.

112 Schizophrenia. We used summary data from the most recent Psychiatric Genomics

113 Consortium (PGC) GWAS of schizophrenia²¹, which identified 294 independent genome-

114 wide significant SNPs. Cases mostly included participants diagnosed with schizophrenia

115 (although diagnoses of other psychotic disorders were also included in some samples).

116 Major depressive disorder (MDD). We used summary data from the most recent PGC GWAS

of MDD²², which identified 44 independent genome-wide significant SNPs. Cases of MDD

118 were either diagnosed by a clinical professional, or through structured interviews with

119 trained interviewers, using the DSM IV, ICD-9 or ICD-10 criteria.

120 *Anxiety.* We used summary data from a GWAS of anxiety²³, which identified one

121 independent genome-wide significant SNP. In this meta-analysis, there were up to five

122 different anxiety disorder phenotypes included in the nine samples from seven independent

123 cohorts. Lifetime DSM-based anxiety disorder diagnostic assessments were available for all

124 cohorts except for the Rotterdam study, in which only one-year prevalence was assessed.

125 Each study assessed DSM-based criteria for the following six-lifetime clinical phenotypes:

126 generalised anxiety disorder (GAD), panic disorder, agoraphobia, social phobia, specific

127 phobia and MDD, however, any subject reporting a mood disorder only was removed from

analyses.

129 *Smoking initiation*. We used summary data from the most recent GWAS of smoking

130 initiation²⁴, which identified 378 conditionally independent genome-wide significant SNPs

131 associated with ever being a regular smoker (current or former). Participants were asked 132 whether they had smoked more than 100 cigarettes in their lifetime and whether they had 133 ever smoked every day for at least a month or ever smoked regularly. To obtain summary 134 statistics for the full sample included in the GWAS and Sequencing Consortium of Alcohol 135 and Nicotine use (GSCAN) GWAS excluding UK Biobank data, we meta-analysed results from 136 GWAS of 23andMe, Inc. only data and all results excluding UK Biobank and 23andMe. The 137 meta-analysis was conducted using the genome-wide association meta-analysis (GWAMA) software²⁷. 138


Drinks per week. We used summary data from the most recent GWAS of drinks per week²⁴, 139 140 which identified 99 conditionally independent genome-wide significant SNPs associated 141 with the average number of drinks a participant reported drinking each week. Participants 142 were asked about the number of alcoholic beverages they had in the past week and the 143 average number of drinks per week than they had in the past year. Data were log-144 transformed prior to the GWAS. This measure did not account for the type of alcohol 145 consumed and for any study with ranges, the mid-range value was used. Again, to obtain 146 summary statistics for the full GSCAN GWAS excluding UK Biobank data, we meta-analysed 147 results from GWAS of 23andMe only data and all results excluding UK Biobank and 148 23andMe.

Alcohol Dependence. We used summary data from the PGC substance use disorders working
 group GWAS of alcohol dependence²⁵, which identified one conditionally independent
 genome-wide significant SNPs in their European GWAS associated with alcohol dependence.
 Alcohol dependence cases were those that met criteria for DSM-IV or DSM-III-R alcohol
 dependence diagnosis.

Cannabis Use Disorder (CUD). We used summary data from the most recent GWAS of CUD²⁶
from the PGC substance use disorders working group, iPSYCH and deCODE which identified
2 conditionally independent genome-wide significant SNPs associated with CUD. CUD cases
were those that met criteria for DSM-5, DSM-IV, DSM-III-R or ICD-10 cannabis abuse or
dependence.

159 Statistical analyses

- 160 The analysis plan for this study was pre-registered on the Open Science Framework
- 161 (https://osf.io/j3tb5). We conducted two-sample MR analyses using R (version 4.0.3)²⁸ and
- 162 the package TwoSampleMR (version 0.5.0)^{29,30}. In order to assess potential bidirectional
- 163 pathways, we conducted two-sample MR analyses with cEF as the exposure for one
- direction, and as the outcome in the other direction (see Figure 1), when assessing causal
- 165 relationships with liability to schizophrenia, MDD, anxiety, smoking initiation, drinks per
- 166 week, alcohol dependence and CUD.
- 167 **Figure 1**. Bidirectional two-sample Mendelian randomisation between a common executive
- 168 function factor score and liability to mental health and substance use outcomes



169

Directed acyclic graph for the potential causal effects being examined with a) executive function as
the exposure and liability to mental health and substance use phenotypes as the outcomes and b)
liability to mental health and substance use phenotypes as the exposures and executive function as

173 the outcome. MDD=Major depressive disorder, CUD=Cannabis use disorder

We used independent genome-wide significant SNPs for the exposure of interest as 174 175 instruments in the MR analyses, except when anxiety, alcohol dependence and CUD were the exposures, where we used a p-value threshold of 1x10⁻⁰⁵ to select SNPs due to the low 176 177 number of genome-wide significant SNPs. We excluded all SNPs in linkage disequilibrium 178 (LD) using an r² of 0.001, a window of 10000 kb and the European 1000 genomes reference 179 panel. Where there were palindromic SNPs, we tried to infer the positive strand based on 180 allele frequencies, but if this was not possible, then these SNPs were also excluded. Where 181 an exposure SNP was not available in the outcome data, we attempted to identify a suitable proxy SNP using the LDproxy tool from LDlink³¹. We pruned the SNPs extracted to $r^2 \ge 0.8$ and 182

183 extracted the first SNP that was present in the exposure and outcome data. After exclusions 184 and identifying any proxy SNPs we searched for the remaining cEF SNPs in the outcome 185 GWAS (73 for schizophrenia, 85 for MDD, 83 for anxiety, 82 for smoking initiation, 83 for drinks per week, 73 for alcohol dependence and 73 for CUD) and the remaining mental 186 187 health and substance use exposure SNPs in the cEF outcome (175 for schizophrenia, 29 for 188 MDD, 17 for anxiety, 187 for smoking initiation, 67 for drinks per week, 19 for alcohol dependence and 37 for CUD). The GWAS summary statistics for the exposure and outcome 189 190 in each analysis were harmonised so that the SNP allele-exposure and SNP allele-outcome 191 associations were in the same direction. 192 We used several different MR methods to assess these putative causal relationships: inverse-variance weighted (IVW)³², MR-Egger³³, weighted median³⁴, simple mode and 193 weighted mode³⁵, and Steiger filtering³⁶ MR methods. We used the IVW approach as our 194 195 main method with the other methods used as sensitivity analyses.

196 The IVW approach constrains the intercept to pass through zero, assuming no horizontal 197 pleiotropy. We tested for heterogeneity between the individual SNPs included in the genetic 198 instrument using Cochran's test of heterogeneity. The MR-Egger method tests for overall 199 directional pleiotropy by not constraining the intercept to pass through zero. If the intercept 200 is not zero then this is indicative of directional horizontal pleiotropy. We also assessed 201 heterogeneity between the individual SNPs whilst adjusting for any directional pleiotropy 202 for the MR-Egger method using Rucker's Q test. We used the weighted median method to 203 obtain estimates under the assumption that at least 50% of the SNPs satisfy the MR 204 assumptions and are valid IVs. Finally, we used the mode-based approaches to obtain 205 estimates for the largest cluster of SNPs, where SNPs not in that cluster could be invalid. The

weighted method accounts for the largest weights of SNPs. We also conducted single SNPand leave-one-out analyses.

208 Where we found evidence of a bidirectional causal relationship, we ran Steiger filtering. This 209 allows orientation of the direction of effect where the underlying biology of genetic variants 210 is less clear, by identifying which SNPs explain more variance in the outcome than the 211 exposure and then repeating the MR analyses excluding those SNPs to rule out reverse 212 causation³⁶.

213 In cases where we found evidence for a causal effect between a given exposure and 214 outcome, we present plots of these results in the Supplementary Material. These plots 215 include scatter plots of the SNP-exposure and SNP-outcome associations with the causal 216 effect estimates from each MR method presented, forest plots for causal effects of each 217 SNP in the instrument (which can indicate if heterogeneity is present), plots presenting the 218 leave-one-out results and funnel plots of each SNP included in the instrument, where a symmetrical plot indicates that the effects of each SNP included are similar to the average 219 220 effect and asymmetry may indicate horizontal pleiotropy.

221 We calculated weighted and unweighted regression dilution I-squared statistics for each 222 analysis³⁷, presented in Supplementary Table S1, which give an indication of the amount of bias in the 'NO Measurement Error' (NOME) assumption in the MR-Egger estimate³⁴. If the I-223 224 squared statistic is 0.9 or above this indicates minimal bias in the MR-Egger estimate and 225 therefore we present the MR-Egger results for these associations. If either the weighted or 226 unweighted I-squared statistics were between 0.6 and 0.9, this may indicate regression 227 dilution bias and therefore we ran simulation extrapolation (SIMEX) corrections, to obtain 228 bias-adjusted point estimates for MR-Egger and we present these results in place of MR-

229	Egger. Anything below 0.6 means that the bias may be too large and therefore we do not
230	report either the SIMEX correction or the MR-Egger results. We also estimated the mean F-
231	statistic for each analysis, indicative of instrument strength, where a value under 10 may
232	indicate a weak instrument ³⁷ .
233	Data availability
234	The data used in this study are publicly-available GWAS data for cEF (available upon request
235	by contacting the authors), schizophrenia (<u>https://www.med.unc.edu/pgc/download-</u>
236	results/scz/), MDD (<u>https://www.med.unc.edu/pgc/download-results/mdd/</u>), anxiety
237	(https://www.med.unc.edu/pgc/download-
238	results/angst/?choice=Other+GWAS+DataAnxiety+Neuro+Genetics+Study+%28ANGST%29),
239	smoking initiation and drinks per week (data with UK Biobank and 23andMe removed can

- 240 be found here: <u>https://conservancy.umn.edu/handle/11299/201564</u>, and for 23andMe data
- 241 access needs to be requested (see below), alcohol dependence
- 242 (https://figshare.com/articles/dataset/sud2018-alc/14672187) and CUD
- 243 (https://figshare.com/articles/dataset/sud2020-cud/14842692). The full GWAS summary
- statistics for the 23andMe discovery data set will be made available through 23andMe to
- 245 qualified researchers under an agreement with 23andMe that protects the privacy of the
- 246 23andMe participants. Please visit https://research.23andme.com/collaborate/#dataset-
- 247 access/ for more information and to apply to access the data.
- 248 Code availability

- 249 The analysis code that forms the basis of the results presented here is available from the
- 250 University of Bristol's Research Data Repository (http://data.bris.ac.uk/data/), DOI : To be
- 251 made available upon publication).

252 Results

Our two-sample MR results for the causal effects of cEF on mental health and substance useoutcomes are presented in Table 2.

255 Schizophrenia. We found strong evidence of a causal effect of increased cEF on reduced 256 odds of schizophrenia (IVW: OR=0.10; 95% CI 0.05 to 0.19; p-value=3.43x10⁻¹²) for all 257 methods except MR Egger, which we were unable to estimate due to violation of the NOME 258 assumption (See Supplementary Table S1). These results were in a consistent direction 259 across the different MR analyses (Supplementary Figure S1). However, we did observe 260 evidence of heterogeneity for the IVW estimate (Supplementary Figure S2) and some 261 asymmetry in the funnel plot (Supplementary Figure S3), although our leave one out 262 analyses did not indicate that a single SNP was driving the association (Supplementary 263 Figure S4). Steiger filtering indicated that only 41% of SNPs instrumenting cEF explained 264 more variance in cEF than schizophrenia, and results were attenuated when repeating 265 analyses with this subset of SNPs. However, these results were in the same direction as the 266 main results (Supplementary Table 2).

267 Major depressive disorder. We found strong evidence of a causal effect of increased cEF on 268 reduced odds of MDD (IVW: OR=0.52; 95% CI 0.38 to 0.72; p-value=5.23x10⁻⁰⁵). These 269 results were in a consistent direction across the different MR analyses (Supplementary 270 Figure S5), and there was evidence of a causal effect for all methods except simple mode 271 and MR Egger, which again we unable to estimate due to violation of the NOME 272 assumption. Here we also found evidence of heterogeneity for the IVW estimate 273 (Supplementary Figure S6), and some asymmetry in the funnel plot (Supplementary Figure 274 S7); however, leave one out analyses did not indicate that a single SNP was driving the

association (Supplementary Figure S8). Steiger filtering indicated that 81% of SNPs

276 instrumenting cEF explained more variance in cEF than MDD, but again results were similar

to the main results when using this subset of SNPs (Supplementary Table 2).

Anxiety. We did not find evidence of a causal effect of cEF on anxiety liability (IVW: OR=0.49;
95% CI 0.19 to 1.23; p-value=0.13).

280 *Smoking initiation.* We did not find clear evidence of a causal effect of cEF on smoking
281 initiation (IVW: OR=0.87; 95% CI 0.74 to 1.02; p-value=0.09) for any of the MR analyses.

282 Drinks per week. We found some evidence of a causal effect of increased cEF on decreased 283 number of alcoholic drinks per week consumed (IVW: β=-0.06; 95% CI -0.10 to -0.02; p-284 value=0.003). These results were in a consistent direction across the different MR analyses 285 (Supplementary Figure S9), although there was only evidence of a causal effect for the IVW 286 method. We also found evidence of heterogeneity here (Supplementary Figure S10) and 287 slight asymmetry in the funnel plot (Supplementary Figure S11); however, leave one out 288 analyses did not indicate that a single SNP was driving the association (Supplementary 289 Figure S12).

Alcohol dependence. We did not find clear evidence of a causal effect of cEF on alcohol
dependence liability (IVW: OR=0.50; 95% CI 0.23 to 1.28; p-value=0.08) for any of the MR
analyses.

Cannabis Use Disorder (CUD). We found strong evidence of a causal effect of increased cEF
 on reduced odds of CUD (IVW: OR=0.27; 95% CI 0.12 to 0.61; p-value=1.58x10⁻⁰³) for all
 methods except MR Egger, which we were unable to estimate due to violation of the NOME
 assumption (See Supplementary Table S1). These results were in a consistent direction

across the different MR analyses (Supplementary Figure S13). However, we did observe
evidence of heterogeneity for the IVW estimate (Supplementary Figure S14) and slight
asymmetry in the funnel plot (Supplementary Figure S15), although our leave one out
analyses did not indicate that a single SNP was driving the association (Supplementary
Figure S16).

302	Table 2. Two-sample Mendelian randomisation results with executive function (cEF) as the exposure.	
-----	--	--

<u></u>	~~	
	112	
	U .D.	

Outcome	Method	NSNPs	OR or beta (95% CI)	P-value	Heterogeneity test p-value	Directional pleiotropy intercept (95% CI; p-value)
Schizophrenia	IVW	73	0.10 (0.05, 0.19)	3.43x10 ⁻¹²	3.52x10 ⁻⁶¹	
	MR Egger ^a	-	-	-	-	-
	Weighted median	73	0.15 (0.09, 0.24)	1.12x10 ⁻¹⁵		
	Simple mode	73	0.11 (0.04, 0.33)	2.04x10 ⁻⁰⁴		
	Weighted mode	73	0.12 (0.05, 0.29)	1.53x10 ⁻⁰⁵		
MDD	IVW	85	0.52 (0.38, 0.72)	5.23x10 ⁻⁰⁵	8.22x10 ⁻⁰³	
	MR Egger ^a	-	-	-	-	-
	Weighted median	85	0.45 (0.30, 0.67)	1.12x10 ⁻⁰⁴		
	Simple mode	85	0.36 (0.13, 1.10)	0.06		
	Weighted mode	85	0.33 (0.12, 0.96)	0.05		
Anxiety	IVW	83	0.49 (0.19, 1.23)	0.13	0.09	
	MR Egger ^b	83	0.39 (3.67x10 ⁻⁴ , 420.28)	0.79		0.002 (-0.05, 0.06; 0.94)
	Weighted median	83	0.31 (0.09, 1.07)	0.07		
	Simple mode	83	0.09 (0.004, 2.03)	0.14		
	Weighted mode	83	0.16 (0.009, 2.99)	0.23		
Smoking initiation	IVW	82	0.87 (0.74, 1.02)	0.09	2.64 x 10 ⁻⁶⁷	
	MR Egger ^a	-	-	-	-	-
	Weighted median	82	0.88 (0.78,0.99)	0.04		
	Simple mode	82	0.81 (0.51,1.29)	0.39		
	Weighted mode	82	0.81 (0.49, 1.37)	0.44		
Drinks per week	IVW	83	-0.06 (-0.10, -0.02)	0.003	8.81x10 ⁻²⁶	
	MR Egger ^a	-	-	-	-	-
	Weighted median	83	-0.05 (-0.08, -0.01)	0.008		
	Simple mode	83	-0.05 (-0.14, 0.04)	0.29		
	Weighted mode	83	-0.04 (-0.12, 0.04)	0.33		
	weighted mode	రర	-0.04 (-0.12, 0.04)	0.33		

Alcohol	IVW	73	0.50 (0.23, 1.09)	0.08	0.17
		75	0.50 (0.25, 1.09)	0.06	0.17
dependence	MR Egger ^a	-	-	-	
	Weighted median	73	0.37 (0.12, 1.14)	0.92	
	Simple mode	73	0.33 (0.02, 5.61)	0.44	
	Weighted mode	73	0.47 (-0.04, 5.36)	0.55	
CUD	IVW	73	0.27 (0.12, 0.61)	1.58x10 ⁻⁰³	6.17x10 ⁻⁰⁹
	MR Egger ^a	-	-	-	
	Weighted median	73	0.14 (0.06, 0.35)	1.84x10 ⁻⁰⁵	
	Simple mode	73	0.05 (0.007, 0.38)	4.56x10 ⁻⁰³	
	Weighted mode	73	0.08 (0.01, 0.47)	7.19x10 ⁻⁰³	

304

^aNO Measurement Error (NOME) assumption violated for MR-Egger and value below 0.6, therefore no results presented. ^bI-squared value between 0.6 and 0.9 so

306 SIMEX correction is presented instead of MR-Egger. MDD=Major depressive disorder, CUD=Cannabis use disorder, OR-odds ratio, CI=confidence interval,

307 *IVW=Inverse-variance weighted, MR=Mendelian randomisation, SNP=Single nucleotide polymorphism.*

308 Our two-sample MR results for causal effects of the mental health and substance use309 phenotypes on cEF are presented in Table 3.

310	Schizophrenia. We found strong evidence of a causal effect of increased odds of
311	schizophrenia on decreased cEF (IVW: β =-0.04; 95% CI -0.04 to -0.03; p-value=3.25x10 ⁻²⁷).
312	These results were in a consistent direction across the different MR analyses
313	(Supplementary Figure S17). However, we did observe evidence of heterogeneity for the
314	IVW estimate (Supplementary Figure S18) and some asymmetry in the funnel plot
315	(Supplementary Figure S19), although there was little evidence of directional pleiotropy
316	from the SIMEX estimate and our leave one out analyses did not indicate that a single SNP
317	was driving the association (Supplementary Figure S20). Steiger filtering indicated that all
318	SNPs instrumenting schizophrenia explained more variance in schizophrenia than cEF;
319	therefore these analyses were not repeated (Supplementary Table 2).
320	MDD. We did not find evidence of a causal effect of MDD liability on cEF (IVW: β =-0.02; 95%
321	CI -0.05 to 0.01; p-value=0.31) using IVW. However, evidence was stronger using other
322	sensitivity methods and the direction of effect was consistent across all approaches i.e., for
323	increased odds of MDD on decreased cEF. Steiger filtering indicated that all SNPs
324	instrumenting schizophrenia explained more variance in MDD than cEF; therefore these
325	analyses were not repeated (Supplementary Table 2).
326	Anxiety. We did not find evidence of a causal effect of anxiety liability on cEF (IVW:
327	β=8.69x10 ⁻⁰⁴ ; 95% CI -0.003 to 0.005; p-value=0.68) for any of the MR analyses.
328	Smoking initiation. We found strong evidence of a causal effect of smoking initiation on
329	decreased cEF (IVW: β=-0.06; 95% CI -0.09 to -0.03; p-value=6.11x10 ⁻⁰⁵) and there was

evidence of this causal effect using the weighted median method but not the other MR
methods, although the direction of effect was consistent (Supplementary Figure S21). We
did find evidence of heterogeneity for the IVW estimate (Supplementary Figure S22) and
slight asymmetry in the funnel plot (Supplementary Figure S23); however, our leave one out
analyses did not indicate that a single SNP was driving the association (Supplementary
Figure S24).

336 *Drinks per week.* We did not find clear evidence of a causal effect of cEF on number of
337 alcoholic drinks per week consumed (IVW: β=-0.007; 95% CI -0.17 to 0.16; p-value=0.93).

338 *Alcohol dependence*. We did not find clear evidence of a causal effect of alcohol dependence 339 liability on cEF (IVW: β =-3.31x10⁻⁰³; 95% CI -8.21x10⁻⁰³ to 1.65x10⁻⁰³; p-value=0.09) for any of 340 the MR analyses.

341 Cannabis Use Disorder (CUD). We did not find clear evidence of a causal effect of CUD

342 liability on cEF (IVW: β =-6.42x10⁻⁰³; 95% CI -0.01 to 9.56x10⁻⁰⁴; p-value=0.09) for any of the

343 MR analyses.

Exposure	Method	NSNPs	Beta (95% CI)	P-value	Heterogeneity test p-value	Directional pleiotropy intercept (95% Cl; p-value)
Schizophrenia	IVW	175	-0.04 (-0.04, -0.03)	3.25x10 ⁻²⁷	3.04x10 ⁻⁷²	· · · ·
	MR Egger ^b	175	-0.05 (-0.07, -0.03)	5.77x10 ⁻⁰⁵		9.0x10 ⁻⁰⁴ (-6.13x10 ⁻⁰⁴ , 0.002; 0.24)
	Weighted median	175	-0.03 (-0.03, -0.02)	8.08x10 ⁻²¹		
	Simple mode	175	-0.04 (-0.06, -0.01)	2.14x10 ⁻⁰³		
	Weighted mode	175	-0.04 (-0.06, -0.02)	7.93x10 ⁻⁰⁴		
MDD	IVW	29	-0.02 (-0.05, 0.01)	0.31	3.45x10 ⁻¹⁹	
	MR Egger ^a	-	-	-	-	-
	Weighted median	29	-0.03 (-0.05, -0.01)	0.01		
	Simple mode	29	-0.04 (-0.08, -0.006)	0.03		
	Weighted mode	29	-0.03 (-0.06, -0.002)	0.04		
Anxiety	IVW	17	8.69x10 ⁻⁰⁴ (-0.003, 0.005)	0.68	0.17	
	MR Egger ^a	-	-	-	-	-
	Weighted median	17	7.19x10 ⁻⁰⁴ (-0.004, 0.006)	0.78		
	Simple mode	17	0.004 (-0.007, 0.01	0.49		
	Weighted mode	17	0.002 (-0.007, 0.01)	0.67		
Smoking	IVW	187	-0.06 (-0.09, -0.03)	6.11x10 ⁻⁰⁵	4.23x10 ⁻⁸⁸	
Initiation	MR Egger ^a	-	-	-	-	-
	Weighted median	187	-0.04 (-0.07, -0.01)	2.61x10 ⁻⁰³		
	Simple mode	187	-0.01(-0.11, 0.08	0.80		
	Weighted mode	187	-0.01(-0.12, 0.09)	0.82		

Table 3. Two-sample Mendelian randomisation results with executive function (cEF) as the outcome.

Drinks per	IVW	67	-0.007 (-0.17, 0.16)	0.93	1.09x10 ⁻⁵¹	
Week	MR Egger ^a	-	-	-	-	-
	Weighted	67	-0.05 (-0.16, 0.07	0.45		
	median					
	Simple mode	67	-0.10 (-0.31, 0.11)	0.34		
	Weighted mode	67	-0.05 (-0.15, 0.06)	0.41		
Alcohol	IVW	19	-3.31x10 ⁻⁰³ (-8.21x10 ⁻	0.19	0.08	
dependence			⁰³ , 1.65x10 ⁻⁰³)			
	MR Egger ^b	19	-3.74x10 ⁻⁰³ (-0.01, 3.66x10 ⁻⁰³⁾	0.33		1.93x10 ⁻⁰⁵ (-1.99x10 ⁻⁰³ , 2.03x10 ⁻⁰³ ; 0.99)
	Weighted	19	-3.67x10 ⁻⁰³ (-9.78x10 ⁻	0.24		
	median		⁰³ , 2.44x10 ⁻⁰³)			
	Simple mode	19	-3.69x10 ⁻⁰³ (-0.01,	0.52		
			7.25x10 ⁻⁰³)			
	Weighted mode	19	-4.28x10 ⁻⁰³ (-0.01,	0.30		
			3.58x10 ⁻⁰³)			
CUD	IVW	37	-6.42x10 ⁻⁰³ (-0.01, -	0.09	1.71x10 ⁻⁰⁸	
			9.56x10 ⁻⁰⁴)			
	MR Egger ^a	-	-	-	-	-
	Weighted	37	-5.16x10 ⁻⁰³ (-0.01,	0.16		
	median		1.98x10 ⁻⁰³)			
	Simple mode	37	-4.65x10 ⁻⁰³ (-0.02,	0.54		
			9.96x10 ⁻⁰³)			
	Weighted mode	37	-3.65x10 ⁻⁰³ (-0.02,	0.61		
			0.01)			

^aNO Measurement Error (NOME) assumption violated for MR-Egger and value below 0.6, therefore no results presented. ^bI-squared value between 0.6 and 0.9 so

347 SIMEX correction is presented instead of MR-Egger. MDD=Major depressive disorder, CUD=Cannabis use disorder, OR-odds ratio, CI=confidence interval,

348 *IVW=Inverse-variance weighted, MR=Mendelian randomisation, SNP=Single nucleotide polymorphism.*

349 Discussion

We examined whether there was evidence of causal effects of cEF on schizophrenia, MDD, anxiety, smoking initiation, drinks per week, alcohol dependence and CUD. We also examined the reverse direction (i.e., causal effects of mental health and substance use on cEF). Evidence of a causal effect in both directions may be indicative of a bidirectional relationship or some other underlying common risk factor.

355 Our main findings were evidence of a causal relationship between increased cEF and 356 reduced schizophrenia liability in both directions. Steiger filtering supported the finding of 357 bidirectional effects, despite some attenuation of results for cEF on schizophrenia. This 358 causal effect supports previous observational studies, which have found that people with schizophrenia have poorer EF^{1,3–5}; however, our MR analyses provide evidence that these 359 360 associations may reflect causal pathways. The fact that we find causal effects between 361 schizophrenia liability and cEF in both directions may point to this association being 362 bidirectional or due to an underlying common risk factor.

363 The observed causal effect of increased cEF on reduced MDD liability is also interesting, as 364 previous studies have provided mixed evidence for the directionality of this relationship^{6,7}. 365 We did not find strong evidence of a causal effect of MDD on cEF using the IVW approach; 366 however, evidence was stronger when using other MR methods, and the direction of effect 367 we observed was negative and consistent across these. It may also be possible that there is 368 lower power in the MDD instrument than the cEF instrument, due to the lower number of 369 SNPs, which may also be why we do not observe a consistent effect of MDD on cEF. 370 Therefore, we cannot rule out the possibility of a bidirectional relationship and Steiger 371 filtering suggested that the effects could be bidirectional as well. We cannot draw any

strong conclusions from our results regarding anxiety and cEF. Whilst we do not find
evidence of a causal relationship, this does not mean that there is definitely no effect, but
rather that our study may have lacked the power to detect a causal effect here, particularly
given that we find some evidence of a possible causal effect of MDD on cEF in our sensitivity
analyses and previous studies have reported high genetic correlations between MDD and
anxiety³⁸. Thus the association found in previous studies needs further investigation still^{8,9}.

Finally, we also found some evidence of a causal effect of smoking initiation on decreased
cEF and increased cEF on decreased drinks per week and reduced CUD liability, all in a
consistent direction with previous observational studies^{10–14}. However, evidence for the
smoking and drinks per week findings was weak, so further studies examining this would be
useful.

383 Our results are in contrast to a previous study which used latent causal variable (LCV) 384 analyses and did not find evidence of any causal effects of cEF on schizophrenia, MDD, anxiety, alcohol use disorder or other traits examined¹⁶. LCV analysis relies on the 385 386 assumption that there is a latent variable that mediates the genetic correlation between 387 two traits and uses whole genome summary statistics to estimate genetic causality. One trait is partially genetically causal for the other if it is strongly genetically correlated with the 388 389 LCV. However, LCV aims to capture the overall direction of causality and therefore may be 390 less appropriate for relationships where a bidirectional effect may be present, as we 391 observe in our study. Whereas MR does allow for for bidirectional relationships³⁹. Although, LCV has better control for pleiotropy¹⁶, meaning the difference between our results and 392 393 those in the previous LCV analysis may reflect the presence of pleiotropy, which we were 394 unable to directly test for in several of our analyses. We were able to test this for our MR of

395 schizophrenia on cEF and found no evidence of pleiotropy. However, this should be396 considered when interpreting our other results.

397 Limitations

398 There are a number of limitations to our study that should be considered when interpreting 399 these results. First, there could be low statistical power to detect causal effects for some of 400 the analyses. In particular, where anxiety, alcohol dependence and CUD are the exposures 401 there were a low number of genome-wide significant SNPs. To overcome this issue we lowered the p-value threshold for our MR analyses to 1x10⁻⁵, but this means that any 402 403 interpretation of these results should be approached with caution and revisiting this causal 404 relationship when larger GWAS are available would be valuable. Second, in the majority of 405 our analyses (i.e., in both directions for schizophrenia, MDD, smoking initiation, drinks per 406 week and CUD) evidence of heterogeneity was observed in the IVW estimates, which could 407 suggest that horizontal pleiotropy is present (e.g., that independent pathways are 408 responsible for the influence of SNPs on the exposure and outcome). Therefore, caution 409 should be used when interpreting these results. However, we did test for violations of other 410 MR assumptions using additional MR sensitivity analyses and the direction of the results 411 were consistent with the direction of the main results. Despite this, in a number of our 412 analyses we could not test for directional pleiotropy due to the I-squared estimate being too 413 low.

Finally, MR is also subject to some general limitations⁴⁰. For example, the 'Winner's curse'
can occur when the SNPs used are based on the discovery GWAS only (as opposed to
combined discovery and replication results), meaning that SNP-trait effects may be
overestimated. This can mean that the MR estimate is biased towards the null. Thus, the

418 focus of our results is on the direction of effect as opposed to the size of any causal effects,

419 although the latter may still be somewhat informative.

420 Conclusion

421 Our findings suggest a bidirectional causal relationship between cEF and schizophrenia 422 liability, where increased schizophrenia liability is associated with decreased cEF and vice 423 versa, as well as causal effects of increased cEF on reduced MDD liability and CUD liability 424 and decreased drinks per week, and a causal effect of smoking initiation on decreased cEF. 425 These results require further study to better understand the mechanisms behind these 426 causal effects. Future research would benefit from better powered GWAS for anxiety where 427 a lack of power may explain why we did not detect any causal effects. Our results may 428 inform prioritisation of experimental medicine studies (e.g., of interventions targeting EF) to 429 improve the likelihood of successful translation and suggest that these interventions may be 430 useful prior to the onset of schizophrenia and MDD in particular.

Acknowledgements: We thank all the contributors to the consortia we have used GWAS
results from in our analyses. We would like the thank the research participants and
employees of 23andMe for making this work possible.

434 **Funding:** This work was supported by the UK Medical Research Council Integrative

435 Epidemiology Unit at the University of Bristol (Grant ref: MC_UU_00011/7) and the NIHR

436 Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the

437 University of Bristol. HMS is supported by the European Research Council (Grant ref: 758813

438 MHINT). The views expressed in this publication are those of the author(s) and not

439 necessarily those of the NHS, the National Institute for Health Research or the Department

440 of Health and Social Care. ASH acknowledges funding from that National Institute on Drug

441 Abuse (Grant ref: T32DA007261).

442 Competing interests: None

443 **Author contributions:** Conceptualization: MRM, ZER; Methodology: SMIB, ZER; Formal

444 Analysis: SMIB, ZER; Resources: MRM; Data Curation: ZER; Writing—Original Draft: SMIB,

445 ZER; Writing—Review and Editing: SMIB, HMS, ASH, MRM, ZER; Supervision: MRM, ZER;

446 Project Administration: MRM, ZER; Funding Acquisition: MRM.

447 **References**

448	1.	Snyder, H. R., Miyake, A. & Hankin, B. L. Advancing understanding of executive
449		function impairments and psychopathology: Bridging the gap between clinical and
450		cognitive approaches. Front. Psychol. 6, 328 (2015).
451	2.	Kim-Spoon, J. et al. Executive functioning and substance use in adolescence:
452		Neurobiological and behavioral perspectives. Neuropsychologia 100, 79–92 (2017).
453	3.	Thai, M. L., Andreassen, A. K. & Bliksted, V. A meta-analysis of executive dysfunction
454		in patients with schizophrenia: Different degree of impairment in the ecological
455		subdomains of the Behavioural Assessment of the Dysexecutive Syndrome. Psychiatry
456		Research vol. 272 230–236 (2019).
457	4.	Fioravanti, M., Bianchi, V. & Cinti, M. E. Cognitive deficits in schizophrenia: An
458		updated metanalysis of the scientific evidence. BMC Psychiatry 12, 64 (2012).
459	5.	Thuaire, F. et al. Executive functions in schizophrenia aging: Differential effects of age
460		within specific executive functions. <i>Cortex</i> 125 , 109–121 (2020).
461	6.	Rock, P. L., Roiser, J. P., Riedel, W. J. & Blackwell, A. D. Cognitive impairment in
462		depression: a systematic review and meta-analysis. Psychol. Med. 44, 2029–40
463		(2014).
464	7.	Schwert, C., Stohrer, M., Aschenbrenner, S., Weisbrod, M. & Schröder, A.
465		Neurocognitive profile of outpatients with unipolar depressive disorders. J. Clin. Exp.
466		Neuropsychol. 41 , 913–924 (2019).

467 8. Gulpers, B., Lugtenburg, A., Zuidersma, M., Verhey, F. R. J. & Voshaar, R. C. O. Anxiety

disorders and figural fluency: A measure of executive function. J. Affect. Disord. 234, 468 469 38-44 (2018). 470 9. Murphy, Y. E. et al. An Investigation of Executive Functioning in Pediatric Anxiety. 471 Behav. Modif. 42, 885–913 (2018). 472 10. Glass, J. M. et al. Effects of alcoholism severity and smoking on executive 473 neurocognitive function. Addiction 104, 38-48 (2009). 474 11. Heffernan, T. M., Carling, A., O'Neill, T. S. & Hamilton, C. Smoking impedes executive function and related prospective memory. Ir. J. Psychol. Med. 31, 159–165 (2014). 475 476 12. Lundqvist, T. Cognitive consequences of cannabis use: Comparison with abuse of 477 stimulants and heroin with regard to attention, memory and executive functions. 478 Pharmacol. Biochem. Behav. 81, 319–330 (2005). 479 13. Lorenzetti, V., Hoch, E. & Hall, W. Adolescent cannabis use, cognition, brain health 480 and educational outcomes: A review of the evidence. Eur. Neuropsychopharmacol. 481 **36**, 169–180 (2020). 482 14. Martins, J. S., Bartholow, B. D., Cooper, M. L., Von Gunten, C. D. & Wood, P. K. 483 Associations between executive functioning, affect-regulation drinking motives, and 484 alcohol use and problems. Psychol. Addict. Behav. 32, 16–28 (2018). 485 15. Diamond, A. & Ling, D. S. Conclusions about interventions, programs, and approaches 486 for improving executive functions that appear justified and those that, despite much hype, do not. Dev. Cogn. Neurosci. 18, 34-48 (2016). 487 488 16. Hatoum, A. S. et al. Genome-Wide Association Study of Over 427,000 Individuals

489		Establishes Executive Functioning as a Neurocognitive Basis of Psychiatric Disorders
490		Influenced by GABAergic Processes. <i>bioRxiv</i> 674515 (2020) doi:10.1101/674515.
491	17.	Davey Smith, G. & Ebrahim, S. 'Mendelian randomization': Can genetic epidemiology
492		contribute to understanding environmental determinants of disease? International
493		Journal of Epidemiology vol. 32 1–22 (2003).
494	18.	Gupta, V., Walia, G. K. & Sachdeva, M. P. 'Mendelian randomization': an approach for
495		exploring causal relations in epidemiology. <i>Public Health</i> vol. 145 113–119 (2017).
496	19.	Carnegie, R. et al. Mendelian randomisation for nutritional psychiatry. The lancet.
497		Psychiatry 7 , 208–216 (2020).
498	20.	Miyake, A. et al. The Unity and Diversity of Executive Functions and Their
499		Contributions to Complex 'Frontal Lobe' Tasks: A Latent Variable Analysis. Cogn.
500		<i>Psychol.</i> 41 , 49–100 (2000).
501	21.	Schizophrenia Working Group of the Psychiatric Genomics Consortium., Ripke, S.,
502		Walters, J. T. & O'Donovan, M. C. Mapping genomic loci prioritises genes and
503		implicates synaptic biology in schizophrenia. <i>medRxiv</i> 2020.09.12.20192922 (2020)
504		doi:10.1101/2020.09.12.20192922.
505	22.	Wray, N. R. et al. Genome-wide association analyses identify 44 risk variants and
506		refine the genetic architecture of major depression. <i>Nat. Genet.</i> 50 , 668–681 (2018).
507	23.	Otowa, T. et al. Meta-analysis of genome-wide association studies of anxiety
508		disorders. <i>Mol. Psychiatry</i> 21 , 1391–1399 (2016).
509	24.	Liu, M. et al. Association studies of up to 1.2 million individuals yield new insights into

510 the genetic etiology of tobacco and alcohol use. *Nature Genetics* vol. 51 237–244
511 (2019).

512 25. Walters, R. K. *et al.* Transancestral GWAS of alcohol dependence reveals common
513 genetic underpinnings with psychiatric disorders. *Nat. Neurosci.* 21, 1656–1669
514 (2018).

- 515 26. Johnson, E. C. *et al.* A large-scale genome-wide association study meta-analysis of 516 cannabis use disorder. *The Lancet Psychiatry* **7**, 1032–1045 (2020).
- 517 27. Mägi, R. & Morris, A. P. GWAMA: Software for genome-wide association meta-
- analysis. *BMC Bioinformatics* **11**, 288 (2010).
- 519 28. R Core Team. R: A language and environment for statistical computing. (2016).
- Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal relationship between
 imprecisely measured traits using GWAS summary data. *PLOS Genet.* 13, e1007081
- 522 (2017).
- 523 30. Hemani, G. *et al.* The MR-base platform supports systematic causal inference across
 524 the human phenome. *Elife* 7, 1–29 (2018).
- 525 31. Machiela, M. J. & Chanock, S. J. LDlink: A web-based application for exploring
- 526 population-specific haplotype structure and linking correlated alleles of possible
- 527 functional variants. *Bioinformatics* **31**, 3555–3557 (2015).
- 32. Burgess, S., Butterworth, A. & Thompson, S. G. Mendelian randomization analysis
 with multiple genetic variants using summarized data. *Genet. Epidemiol.* 37, 658–665
 (2013).

531	33.	Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid
532		instruments: Effect estimation and bias detection through Egger regression. Int. J.
533		Epidemiol. 44 , 512–525 (2015).
534	34.	Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent Estimation in
535		Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
536		Estimator. Genet. Epidemiol. 40, 304–314 (2016).
537	35.	Hartwig, F. P., Davey Smith, G. & Bowden, J. Robust inference in summary data
538		Mendelian randomization via the zero modal pleiotropy assumption. Int. J. Epidemiol.
539		(2017) doi:10.1093/ije/dyx102.
540	36.	Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal relationship between
541		imprecisely measured traits using GWAS summary data. PLoS Genet. 13, e1007081
542		(2017).
542 543	37.	(2017). Bowden, J. <i>et al.</i> Assessing the suitability of summary data for two-sample mendelian
	37.	
543	37.	Bowden, J. <i>et al.</i> Assessing the suitability of summary data for two-sample mendelian
543 544	37. 38.	Bowden, J. <i>et al.</i> Assessing the suitability of summary data for two-sample mendelian randomization analyses using MR-Egger regression: The role of the I 2 statistic. <i>Int. J.</i>
543 544 545		Bowden, J. <i>et al.</i> Assessing the suitability of summary data for two-sample mendelian randomization analyses using MR-Egger regression: The role of the I 2 statistic. <i>Int. J. Epidemiol.</i> 45 , 1961–1974 (2016).
543 544 545 546		Bowden, J. <i>et al.</i> Assessing the suitability of summary data for two-sample mendelian randomization analyses using MR-Egger regression: The role of the I 2 statistic. <i>Int. J. Epidemiol.</i> 45 , 1961–1974 (2016). Hettema, J. M. What is the genetic relationship between anxiety and depression? <i>Am.</i>
543 544 545 546 547	38.	Bowden, J. <i>et al.</i> Assessing the suitability of summary data for two-sample mendelian randomization analyses using MR-Egger regression: The role of the I 2 statistic. <i>Int. J.</i> <i>Epidemiol.</i> 45 , 1961–1974 (2016). Hettema, J. M. What is the genetic relationship between anxiety and depression? <i>Am.</i> <i>J. Med. Genet. Part C Semin. Med. Genet.</i> 148C , 140–146 (2008).
543 544 545 546 547 548	38.	 Bowden, J. <i>et al.</i> Assessing the suitability of summary data for two-sample mendelian randomization analyses using MR-Egger regression: The role of the I 2 statistic. <i>Int. J. Epidemiol.</i> 45, 1961–1974 (2016). Hettema, J. M. What is the genetic relationship between anxiety and depression? <i>Am. J. Med. Genet. Part C Semin. Med. Genet.</i> 148C, 140–146 (2008). Hines, L. A., Treur, J. L., Jones, H. J., Sallis, H. M. & Munafò, M. R. Using genetic

552 (2016).